
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Cancer Research, Vol 2, Issue 7 1231-1237, Copyright © 1996 by American Association for Cancer Research
ARTICLES |
M Filipits, RW Suchomel, G Dekan, K Haider, G Valdimarsson, D Depisch and R Pirker
Department of Oncology, Clinic for Internal Medicine I, and Department of Pathology, University of Vienna Medical School, A-1090 Vienna, Australia.
To evaluate the clinically important mechanisms of drug resistance in breast cancer, the expression of the MRP gene and the corresponding one for the MDR1 gene were determined in primary breast carcinoma specimens by both reverse transcription-PCR (n = 134) and immunohistochemistry (n = 63). Expression of MRP RNA was observed in all breast cancer specimens. MDR1 RNA was detected in 80 (60%) of the carcinomas. Staining with monoclonal antibodies QCRL-1 and QCRL-3, which both recognize MRP, was strong in 15 (24%) and weak in the remaining 48 specimens (76%). Staining with C219, which recognizes P-glycoprotein, was strong in 6 (9%), weak in 30 (48%), and negative in 27 (43%) of the samples. Strong MRP staining was more frequent in T3 and T4 tumors than in T1 and T2 tumors and in the primary tumors of patients with distant metastases but was independent of age, menopausal status, histology, histological grade, estrogen receptor, progesterone receptor, and lymph node involvement. No correlation between MRP staining and expression of MDR1 RNA or P-glycoprotein was observed. Thus, these results indicate expression of both the MRP gene and the MDR1 gene in primary breast carcinomas and suggest that clinical drug resistance in breast cancer is most likely multifactorial.
This article has been cited by other articles:
![]() |
S. P. Newman, P. A. Foster, C. Stengel, J. M. Day, Y. T. Ho, J.-G. Judde, M. Lassalle, G. Prevost, M. P. Leese, B. V.L. Potter, et al. STX140 Is Efficacious In vitro and In vivo in Taxane-Resistant Breast Carcinoma Cells Clin. Cancer Res., January 15, 2008; 14(2): 597 - 606. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Deeley, C. Westlake, and S. P. C. Cole Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins. Physiol Rev, July 1, 2006; 86(3): 849 - 899. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-H. Wang, D. A. Scollard, S. Teng, R. M. Reilly, and M. Piquette-Miller Detection of P-Glycoprotein Activity in Endotoxemic Rats by 99mTc-Sestamibi Imaging J. Nucl. Med., September 1, 2005; 46(9): 1537 - 1545. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Filipits, G. Pohl, M. Rudas, O. Dietze, S. Lax, R. Grill, R. Pirker, C. C. Zielinski, H. Hausmaninger, E. Kubista, et al. Clinical Role of Multidrug Resistance Protein 1 Expression in Chemotherapy Resistance in Early-Stage Breast Cancer: The Austrian Breast and Colorectal Cancer Study Group J. Clin. Oncol., February 20, 2005; 23(6): 1161 - 1168. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.-W. Zhang, H.-M. Gu, D. Situ, A. Haimeur, S. P. C. Cole, and R. G. Deeley Functional Importance of Polar and Charged Amino Acid Residues in Transmembrane Helix 14 of Multidrug Resistance Protein 1 (MRP1/ABCC1): IDENTIFICATION OF AN ASPARTATE RESIDUE CRITICAL FOR CONVERSION FROM A HIGH TO LOW AFFINITY SUBSTRATE BINDING STATE J. Biol. Chem., November 14, 2003; 278(46): 46052 - 46063. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. Leonard, T. Fojo, and S. E. Bates The Role of ABC Transporters in Clinical Practice Oncologist, October 1, 2003; 8(5): 411 - 424. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Sciuto, R. Pasqualoni, S. Bergomi, G. Petrilli, P. Vici, F. Belli, C. Botti, M. Mottolese, and C. L. Maini Prognostic Value of 99mTc-Sestamibi Washout in Predicting Response of Locally Advanced Breast Cancer to Neoadjuvant Chemotherapy J. Nucl. Med., June 1, 2002; 43(6): 745 - 751. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Kao, S.-C. Tsai, T.-J. Liu, Y.-J. Ho, J.-J. Wang, S.-T. Ho, and S.-P. ChangLai P-Glycoprotein and Multidrug Resistance-related Protein Expressions in Relation to Technetium-99m Methoxyisobutylisonitrile Scintimammography Findings Cancer Res., February 1, 2001; 61(4): 1412 - 1414. [Abstract] [Full Text] |
||||
![]() |
K. Toth, M. M. Vaughan, G. Schwartz, J. S. Winston, B. S. Skenderis II, H. K. Slocum, and Y. M. Rustum Expression of the MRP and MDRI Multidrug Resistance Gene Products in 160 Untreated Human Carcinomas Studied by Immunohistochemical Methods in Formalin-Paraffin Sections International Journal of Surgical Pathology, July 1, 1998; 6(3): 145 - 154. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |